The goal of this randomized clinical trial is to determine whether a biomarker-signature (BV) supported antibiotic treatment decision matrix can have a beneficial impact on antibiotic use and patient outcomes in an ICU population.
Admitted to the Intensive Care Unit (ICU)
Started on antibiotics for any suspected or confirmed infection in the preceding 72 hours (about 3 days)
Treating doctor(s) willing to consider BV test result in antibiotic treatment decision making
Severe immunocompromise/immunosuppression
Congenital immunodeficiency
HIV with CD4 < 20
Active chemotherapy and profound neutropenia (ANC < 100) expected to last > 7 days;
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator